PMID- 9469734
OWN - NLM
STAT- MEDLINE
DCOM- 19980326
LR  - 20191211
IS  - 0031-9384 (Print)
IS  - 0031-9384 (Linking)
VI  - 63
IP  - 3
DP  - 1998 Feb 1
TI  - Persistent hyperactivity following a single intracerebroventricular dose of 
      ouabain.
PG  - 403-6
AB  - Intracerebroventricular (i.c.v.) administration of ouabain has been shown to 
      alter motor activity in the rat. It has been purported that this may model the 
      behavioral abnormalities of human manic-depressive (bipolar) illness. Since 
      manic-depression is a recurrent condition, we elected to investigate the effects 
      of the multiple administration of i.c.v. ouabain. Male Sprague-Dawley rats were 
      allowed to acclimate to the animal facility for 7-10 days after which time i.c.v. 
      cannulae were placed. Animals received two i.c.v. injections of either ouabain 
      (10[-3] M) or artificial cerebrospinal fluid (aCSF) 9 days apart, so that 6 rats 
      received aCSF-aCSF, 6 received ouabain-aCSF, and 6 received ouabain-ouabain. 
      Behavioral activity was evaluated in an open field (86 x 86 cm subdivided into 
      sixteen 21.5 x 21.5-cm squares) for 20 min at baseline and immediately following 
      each i.c.v. injection. After the last behavioral test, the animals were killed, 
      and the brains were rapidly harvested and dissected over ice. Specific ouabain 
      binding and sodium pump activity were determined. A single dose of ouabain 
      produced a marked increase (297.0%, p = 0.002) in open field activity compared to 
      both baseline behavior and to aCSF injected animals. The effects of ouabain 
      appeared to last for 9 days. A second i.c.v. injection of either ouabain (136.5 
      +/- 60.4 SEM) or aCSF (108.0%, p < 0.01) had no effect on the activity level 
      which was intermediate between the initial ouabain hyperactivity and the baseline 
      level. Nine days after ouabain administration, hippocampal ouabain binding was 
      increased relative to the control group (5477 +/- 485.7 vs. 3579 +/- 518.6, p < 
      0.05) and sodium pump activity was relatively lower (2293.8 +/- 265.5 vs. 3174.2 
      +/- 410.5, p < 0.05).
FAU - Ruktanonchai, D J
AU  - Ruktanonchai DJ
AD  - Mood Disorders Research Program, Department of Psychiatry, University of 
      Louisville School of Medicine, Kentucky 40292, USA.
FAU - El-Mallakh, R S
AU  - El-Mallakh RS
FAU - Li, R
AU  - Li R
FAU - Levy, R S
AU  - Levy RS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Physiol Behav
JT  - Physiology & behavior
JID - 0151504
RN  - 0 (Enzyme Inhibitors)
RN  - 5ACL011P69 (Ouabain)
RN  - EC 7.2.2.13 (Sodium-Potassium-Exchanging ATPase)
SB  - IM
MH  - Animals
MH  - Enzyme Inhibitors/administration & dosage/pharmacokinetics/*pharmacology
MH  - Hippocampus/drug effects/metabolism
MH  - Injections, Intraventricular
MH  - Male
MH  - Motor Activity/*drug effects
MH  - Neostriatum/drug effects/metabolism
MH  - Ouabain/administration & dosage/pharmacokinetics/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Sodium-Potassium-Exchanging ATPase/*antagonists & inhibitors
EDAT- 1998/02/20 00:00
MHDA- 1998/02/20 00:01
CRDT- 1998/02/20 00:00
PHST- 1998/02/20 00:00 [pubmed]
PHST- 1998/02/20 00:01 [medline]
PHST- 1998/02/20 00:00 [entrez]
AID - S0031-9384(97)00457-5 [pii]
AID - 10.1016/s0031-9384(97)00457-5 [doi]
PST - ppublish
SO  - Physiol Behav. 1998 Feb 1;63(3):403-6. doi: 10.1016/s0031-9384(97)00457-5.